Coherentmarketinsightsus

  High prevalence of brain tumor is expected to propel growth of the anaplastic astrocytoma treatment market. For instance, according to The Central Brain Tumor Registry of the United States (2020 CBTRUS Statistical Report), the incidence rate of primary malignant and non-malignant brain and other central nervous system tumors in the U.S was 23.79 cases per 100,000 for an overall total count of 415,411 incident tumors. Adoption of combination therapies is expected to supply lucrative growth opportunities for players in the Anaplastic Astrocytoma Treatment Market . For instance, in January 2021, Adastra Pharmaceuticals announced that its Phase Ib trial of oral small molecule drug zotiraciclib in conjunction with the existing standard of care, temozolomide, deminstrted good results in treating patients with recurrent high-grade gliomas (recurrent anaplastic astrocytoma and recurrent glioblastoma). Moreover, increasing quantity of treatment centers for brain tumors i...

High prevalence of brain tumor is expected to propel growth of the anaplastic astrocytoma treatment market. For instance, according to The Central Brain Tumor Registry of the United States (2020 CBTRUS Statistical Report), the incidence rate of primary malignant and non-malignant brain and other central nervous system tumors in the U.S was 23.79 cases per 100,000 for an overall total count of 415,411 incident tumors. Moreover, R&D of new drugs is also expected to aid in growth of the market. For instance, in April 2020, Mateon Therapeutics Inc. announced the publication of a peer-reviewed research articlereporting the analysis of the long-term follow-up data on the recalcitrant/resistant anaplastic astrocytoma patient subpopulation treated in the NCT00431561 study, in the oncology journal Cancer Reports and Reviews. Similarly, in December 2020, KIYATEC, Inc. announced the initial clinical use of its response-prediction test to boost outcomes in relapsed brain cancer p...